We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Astrazeneca Plc | LSE:AZN | London | Ordinary Share | GB0009895292 | ORD SHS $0.25 |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 38.00 | 0.31% | 12,370.00 | 12,368.00 | 12,372.00 | 12,432.00 | 12,314.00 | 12,350.00 | 1,418,212 | 16:29:59 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 45.81B | 5.96B | 3.8415 | 32.20 | 191.76B |
From May 2019 to May 2024
By Adam Clark
AstraZeneca PLC (AZN.LN) said Monday that the U.S. Food & Drug Administration has granted orphan drug designation for potential lung-disease treatment saracatinib.
The drug company said saracatinib has completed phase 1 development as a treatment for idiopathic pulmonary fibrosis, a chronic and normally fatal disease that affects around 100,000 people in the U.S.
"IPF is a recent addition to our respiratory research strategy and we are interested to see whether saracatinib could be a useful approach for the treatment of this intractable disease," Mene Pangalos, executive vice-president at AstraZeneca, said.
Write to Adam Clark at adam.clark@dowjones.com; @AdamDowJones
(END) Dow Jones Newswires
March 18, 2019 03:23 ET (07:23 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
1 Year Astrazeneca Chart |
1 Month Astrazeneca Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
